Cochrane · systematic review · CD012484
Beta‐blockers for suspected or diagnosed acute myocardial infarction
Safi, S, Sethi, NJ, Nielsen, EE, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
5
Included studies
NR
No studies 5 · 35.7%Ungraded 0 · 0%Very low 3 · 21.4%Low 1 · 7.1%Moderate 4 · 28.6%High 1 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at the time point less than three months follow‐up
Population: patients with suspected or diagnosed myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at 'less than 3 months' Beta‐blockers vs placebo or no intervention | RR 0.94 [0.9, 1] | 46 studies · 80452 participants | High |
Serious adverse events at 'less than 3 months' Beta‐blockers vs placebo or no intervention | no estimate extracted | NR | No studies |
MACE (major adverse cardiovascular event) at 'less than 3 months' Beta‐blockers vs placebo or no intervention | no estimate extracted | NR | No studies |
Quality of life at 'less than 3 months' Beta‐blockers vs placebo or no intervention | no estimate extracted | NR | No studies |
Angina at 'less than 3 months' Beta‐blockers vs placebo or no intervention | RR 0.7 [0.25, 1.84] | 3 studies · 98 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality at 'less than 3 months' Beta‐blockers vs placebo or no intervention | RR 0.99 [0.91, 1.08] | 1 study · 45852 participants | Moderate Downgraded: risk of bias, imprecision |
Myocardial infarction at 'less than 3 months' Beta‐blockers vs placebo or no intervention | RR 0.82 [0.74, 0.9] | 18 studies · 67562 participants | Moderate Downgraded: risk of bias, imprecision |
Beta‐blockers versus placebo or no intervention for suspected or diagnosed acute myocardial infarction at maximum follow‐up beyond three months
Population: patients with suspected or diagnosed myocardial infarction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum Beta‐blockers vs placebo or no intervention | RR 0.93 [0.86, 0.99] | 21 studies · 25210 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events at maximum Beta‐blockers vs placebo or no intervention | no estimate extracted | NR | No studies |
MACE (major adverse cardiovascular event) at maximum Beta‐blockers vs placebo or no intervention | RR 0.81 [0.43, 1.52] | 4 studies · 475 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life at maximum Beta‐blockers vs placebo or no intervention | no estimate extracted | NR | No studies |
Angina at maximum Beta‐blockers vs placebo or no intervention | RR 0.64 | 844 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality at maximum Beta‐blockers vs placebo or no intervention | RR 0.9 [0.83, 0.98] | 14 studies · 22457 participants | Moderate Downgraded: risk of bias, imprecision |
Myocardial infarction at maximum Beta‐blockers vs placebo or no intervention | RR 0.89 [0.75, 1.08] | 14 studies · 6825 participants | Low Downgraded: risk of bias, imprecision |